Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.

被引：0
|
作者：
Tun, Aung M.
Wang, Yucai
Maliske, Seth
Farooq, Umar
Micallef, Ivana N. M.
Inwards, David James
Porrata, Luis F.
Ansell, Stephen M.
Rosenthal, Allison Claire
Kharfan-Dabaja, Mohamed
Link, Brian K.
Villasboas, Jose Caetano
Paludo, Jonas
Cerhan, James Robert
Habermann, Thomas Matthew
Witzig, Thomas E.
Nowakowski, Grzegorz S.
Johnston, Patrick B.
机构：
[1] Univ Kansas, Canc Ctr, Westwood, KS USA
[2] Mayo Clin, Div Hematol, Rochester, MN USA
[3] Univ Iowa, Iowa City, IA USA
[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[5] Mayo Clin, Div Hematol, Rochester, MN USA
[6] Mayo Clin, Div Hematol, Phoenix, AZ USA
[7] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA
[8] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e19501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19501
引用
收藏
页数：3
相关论文
共 50 条
  • [41] STATE OF SALVAGE THERAPY FOR RELAPSED AND PRIMARY REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
    Moskowitz, Craig
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (01) : S28 - S29
  • [42] OUTCOME OF RELAPSE OF DIFFUSE LARGE B-CELL LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
    Kaneko, Hiroto
    Kuwahara, Saeko
    Ohshiro, Muneo
    Tsutsumi, Yasuhiko
    Iwai, Toshiki
    Kuroda, Junya
    Horiike, Shigeo
    Yokota, Shohei
    Taniwaki, Masafumi
    ANNALS OF ONCOLOGY, 2014, 25
  • [43] Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
    Matasar, Matthew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (11.5): : 1327 - 1330
  • [44] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [45] Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Rigacci, L.
    Fabbri, A.
    Mappa, S.
    Nassi, L.
    Lenoci, M.
    Puccini, B.
    Alterini, R.
    Chitarrelli, I
    Carrai, V
    Lauria, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 61
  • [46] Modified R-DHAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
    Fabbri, A.
    Rigacci, L.
    Lenoci, M.
    Mappa, S.
    Puccini, B.
    Nassi, L.
    Chitarrelli, I.
    Gozzetti, A.
    Alterini, R.
    Carrai, V.
    Bosi, A.
    Lauria, F.
    ANNALS OF ONCOLOGY, 2008, 19 : 219 - 220
  • [47] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Dickinson, Michael J.
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Bachy, Emmanuel
    Corradini, Paolo
    Iacoboni, Gloria
    Khan, Cyrus
    Wrobel, Tomasz
    Offner, Fritz
    Wu, Shang-Ju
    Cartron, Guillaume
    Hertzberg, Mark
    Sureda, Anna
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Dixon, Mark
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    Trney, Marek
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24): : 2220 - 2231
  • [48] CLINICO-PATHOLOGICAL FEATURES OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: THE IMPACT OF THE TIME TO RELAPSE AS A STRATIFYING FACTOR
    Scapinello, G.
    Pizzi, M.
    Del Bianco, P.
    Bonetto, G.
    Riva, M.
    Branca, A.
    Berno, T.
    Gurrieri, C.
    Vianello, F.
    Visentin, A.
    Zambello, R.
    Tos, A. Dei
    Semenzato, G.
    Trentin, L.
    Piazza, F.
    HAEMATOLOGICA, 2021, 106 (10) : 147 - 147
  • [49] The efficacy of R-ICE therapy as a salvage treatment for relapse and refractory diffuse large B-Cell lymphoma
    Kodaira, Makoto
    Yokoyama, Masahiro
    Asai, Hiroaki
    Yamada, Shuhei
    Ueda, Kyoko
    Myojo, Tomohiro
    Nishimura, Tomoko
    Mishima, Yuko
    Sakajiri, Sakura
    Takeuchi, Kengo
    Saotome, Takashi
    Terui, Yasuhito
    Takahashi, Shunji
    Hatake, Kiyohiko
    BLOOD, 2007, 110 (11) : 180B - 180B
  • [50] A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
    Wagner-Johnston, Nina D.
    Goy, Andre
    Rodriguez, Maria A.
    Ehmann, W. Christopher
    Hamlin, Paul A.
    Radford, John
    Thieblemont, Catherine
    Suh, Cheolwon
    Sweetenham, John
    Huang, Yifan
    Sullivan, Sharon T.
    Vandendries, Erik R.
    Gisselbrecht, Christian
    LEUKEMIA & LYMPHOMA, 2015, 56 (10) : 2863 - 2869
12345